## Claims

1. A method of treating spastic disorders, said method comprising administering to a subject having a spastic disorder a therapeutically effective amount of the compound gamma-aminobutyramide, analogs, substituted forms, derivatives, the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, or compounds which yield gamma-aminobutyramide as an intermediate, a metabolite, or a by-product.

2. A method according to claim 1, wherein said administering step further comprises intrathecally delivering the compound.

3. A method according to claim 1, wherein said administering step further comprises intraventricularly delivering the compound.

4. A method according to claim 1, wherein the compound which yields gamma-aminobutyramide as a solubility product comprises 4-[[(4-chlorophenyl)-(5-fluoro-2-hydroxyphenyl)methylene]amino] butanamide.

5. A method according to claim 1, wherein said administering step further comprises delivering the compound to the subject through an implantable pump.

6. A method according to claim 1, wherein said administering step further comprises delivering the compound to the subject through a spinal catheter.

7. A method according to claim 1, wherein the spastic disorder is spastic hypertonia.

8. A method according to claim 1, wherein the spastic disorder is dystonia.

9. A method according to claim 1, wherein the spasticity or spastic disorder is caused by traumatic brain injury.

10. A method according to claim 2, wherein said intrathecal delivering step comprises delivering the compound through a spinal catheter inserted in a substantially cephalid spinal location.

11. A method for treating convulsions, said method comprising administering to a subject either having convulsions or predisposed to convulsions a therapeutically effective amount of the compound gamma-aminobutyramide, analogs, substituted forms, derivatives, the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, or compounds which yield gamma-aminobutyramide as an intermediate, a metabolite, or a by-product.

12. A method according to claim 11, wherein said administering step further comprises intrathecally delivering the compound.

13. A method according to claim 11, wherein said administering step further comprises intraventricularly delivering the compound.

14. A method according to claim 11, wherein the compound which yields gamma-aminobutyramide as a solubility product comprises 4-[[(4-chlorophenyl)-(5-fluoro-2-hydroxyphenyl)methylene]amino] butanamide.

15. A method according to claim 11, wherein said administering step further comprises delivering the compound to the subject through an implantable pump.

16. A method according to claim 11, wherein said administering step further comprises delivering the compound to the subject through a catheter.

17. A method according to claim 12, wherein said intrathecal delivering step comprises delivering the compound through a spinal catheter inserted in a substantially cephalid spinal location.

18. A method for treating epilepsy, said method comprising intraventricularly administering a therapeutically effective amount of the

compound gamma-aminobutyramide, analogs, substituted forms, derivatives, the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, or compounds which yield gamma-aminobutyramide as an intermediate, a metabolite, or a by-product.

19. A method of treating pain, said method comprising administering to a subject having pain a therapeutically effective amount of the compound gamma-aminobutyramide, analogs, substituted forms, derivatives, the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, or compounds which yield gamma-aminobutyramide as an intermediate, a metabolite, or a by-product.

20. A method according to claim 19, wherein said administering step further comprises intrathecally delivering the compound.

21. A method according to claim 19, wherein said administering step further comprises intraventricularly delivering the compound.

22. A method according to claim 19, wherein the compound which yields gamma-aminobutyramide as a solubility product comprises 4-[[(4-chlorophenyl)-(5-fluoro-2-hydroxyphenyl)methylene]amino] butanamide.

23. A method according to claim 19, wherein said administering step further comprises delivering the compound to the subject through an implantable pump.

24. A method according to claim 19, wherein said administering step further comprises delivering the compound to the subject through a catheter.

25. A method of treating idiopathic dystonia or torsional dystonia, said method comprising administering to a subject having idiopathic dystonia or torsional dystonia a therapeutically effective amount of baclofen.

26. A method of treating idiopathic dystonia or torsional dystonia, said method comprising administering to a subject having idiopathic dystonia or torsional dystonia a therapeutically effective amount of gamma-aminobutyramide.